Rodman & Renshaw initiated coverage on Century Therapeutics with a new price target
$IPSC
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Rodman & Renshaw initiated coverage of Century Therapeutics with a rating of Buy and set a new price target of $6.00